Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs W W Grainger Inc (GWW) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
W W Grainger IncTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs W W Grainger Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.18 (market cap $9.43B), while W W Grainger Inc trades at $1,310.58 (market cap $61.32B). The key difference: W W Grainger Inc is far larger — about 6.5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and W W Grainger Inc pays a 0.77% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIOGWW
Market Cap
$9.43B$61.32B
Sector
HealthTechnology
52-Week High
$356.25$1.40K
52-Week Low
$241.71$918.18
Enterprise Value
$9.18B$63.53B
Dividend Yield
0.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.

The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.

W W Grainger Inc

W.W. Grainger (GWW) trades at $1,308.06, up 0.82% on the day, with strong recent earnings beats in Q1 and Q2 2026. The stock shows a bearish technical signal despite robust fundamentals, including a 47.92% ROE and rising revenue. Analysts maintain a cautious stance with a consensus price target of $1,320, while recent news highlights operational strength and market share gains.

Outlook remains mixed; solid earnings growth and margin expansion support upside, but high valuation multiples and bearish technicals pose near-term risks. Investors should weigh strong cash flow and dividend stability against potential volatility from macroeconomic pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About W W Grainger Inc

Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.

Read more on GWW